← Back to All US Stocks

MDxHealth SA (MDXH) Stock Fundamental Analysis & AI Rating 2026

MDXH Nasdaq Services-Medical Laboratories C9 CIK: 0001872529
Updated This Month • Analysis: Apr 1, 2026 • SEC Data: 2026-04-01
HOLD
5% Conf
Pending
Analysis scheduled

📊 MDXH Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 5% confidence
MDxHealth SA (MDXH) receives a HOLD rating with 5% confidence from our AI fundamental analysis based on SEC 10-K filings. Below is our complete MDXH stock analysis for 2026.

Is MDxHealth SA (MDXH) a Good Investment?

Claude

Cannot assess MDxHealth SA fundamentals due to complete lack of available financial data. No income statement, balance sheet, or cash flow metrics are available in SEC filings.

Why Buy MDxHealth SA Stock? MDXH Key Strengths

Claude
  • + Operates in medical laboratory services sector with potential for recurring revenue
  • + Listed on Nasdaq indicating regulatory compliance
  • + Potential for diagnostic testing market growth

MDXH Stock Risks: MDxHealth SA Investment Risks

Claude
  • ! No financial data available - unable to assess revenue, profitability, or cash flow
  • ! No balance sheet data - liquidity and solvency position unknown
  • ! No operational metrics - cannot evaluate business performance or trends
  • ! No insider trading activity in last 90 days - potential red flag for engagement
  • ! Medical laboratory sector faces intense competition and reimbursement pressure

Key Metrics to Watch

Claude
  • * Revenue and revenue growth rate
  • * Operating margins and path to profitability
  • * Cash position and operating cash flow
  • * Customer concentration and test volume trends
  • * Regulatory and reimbursement rate changes

MDxHealth SA (MDXH) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

MDXH Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

MDXH vs Healthcare Sector: How MDxHealth SA Compares

How MDxHealth SA compares to Healthcare sector averages

Net Margin
MDXH 0.0%
vs
Sector Avg 12.0%
MDXH Sector
ROE
MDXH 0.0%
vs
Sector Avg 15.0%
MDXH Sector
Current Ratio
MDXH 0.0x
vs
Sector Avg 2.0x
MDXH Sector
Debt/Equity
MDXH 0.0x
vs
Sector Avg 0.6x
MDXH Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is MDxHealth SA Stock Overvalued? MDXH Valuation Analysis 2026

Based on fundamental analysis, MDxHealth SA has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

MDxHealth SA Balance Sheet: MDXH Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

MDXH Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

MDXH SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for MDxHealth SA (CIK: 0001872529)

📋 Recent SEC Filings

Date Form Document Action
Nov 14, 2024 SC 13G dmxhealth13g093024t.txt View →
Oct 4, 2024 SC 13G mdxh13g.htm View →
Oct 4, 2024 SC 13G exas-20241004xsc13g.htm View →
Feb 28, 2023 4 xslF345X03/form4.xml View →
Feb 14, 2022 SC 13G sc13g.htm View →

Frequently Asked Questions about MDXH

What is the AI rating for MDXH?

MDxHealth SA (MDXH) has an AI rating of HOLD with 5% confidence, based on fundamental analysis of SEC EDGAR filings.

What are MDXH's key strengths?

Claude: Operates in medical laboratory services sector with potential for recurring revenue. Listed on Nasdaq indicating regulatory compliance.

What are the risks of investing in MDXH?

Claude: No financial data available - unable to assess revenue, profitability, or cash flow. No balance sheet data - liquidity and solvency position unknown.

What is MDXH's revenue and growth?

MDxHealth SA reported revenue of N/A.

Does MDXH pay dividends?

MDxHealth SA does not currently pay dividends.

Where can I find MDXH SEC filings?

Official SEC filings for MDxHealth SA (CIK: 0001872529) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is MDXH's EPS?

MDxHealth SA has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is MDXH a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, MDxHealth SA has a HOLD rating with 5% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is MDXH stock overvalued or undervalued?

Valuation metrics for MDXH: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy MDXH stock in 2026?

Our dual AI analysis gives MDxHealth SA a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is MDXH's free cash flow?

MDxHealth SA's operating cash flow is N/A, with capital expenditures of N/A.

How does MDXH compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 1, 2026 | Data as of: 2026-04-01 | Powered by Claude AI